Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-27.03	-41.31	-43.24	-6	-46.67
Depreciation & Amortization	0.15	0.37	0.46	0.63	0.74
Share-Based Compensation	2.15	2.69	4.23	5.75	7.35
Other Operating Activities	0.8	11.23	1.83	-35.16	1.26
Operating Cash Flow	-23.94	-27.02	-36.72	-34.78	-37.32
Capital Expenditures	-0.03	-0.25	-0.01	-0.08	-0.03
Change in Investments	15.58	-23.03	21.57	44.85	3.28
Investing Cash Flow	15.54	-23.28	21.56	44.77	3.26
Share Issuance / Repurchase	7.86	0	62.16	1.31	0.02
Financing Cash Flow	7.86	0	62.16	1.31	0.02
Net Cash Flow	-0.54	-50.3	47	11.3	-34.04
Free Cash Flow	-23.97	-27.27	-36.72	-34.85	-37.35
Free Cash Flow Per Share	-0.50	-0.59	-0.88	-1.18	-1.27

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).